← Leaderboards
Andrew J Armstrong
Duke University
$4,232,419
Attributed
$7,375,874
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,375,874 · 6
By mechanism
R01$5,339,390 · 2
UH3$1,011,140 · 1
P30$673,736 · 2
UH2$351,608 · 1
Top collaborators
- Susan Halabi10 shared
- Scott M. Dehm5 shared
- Joshua Michael Lang5 shared
- Dana Rathkopf5 shared
Most similar at Duke University
Same institution · by research overlap
- Mary Min-Chin Lee$2,922,536
- Deborah R. Kaye$579,044
- Robert Warren Floyd$105,473
- Jiaoti Huang$7,876,254
- Avner Vengosh$1,304,582
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsMalignant Neoplasm Of ProstateBiological MarkersTumorPredictive MarkerClinical ResearchNeoplasm Circulating CellsMetastatic Prostate CancerAbirateroneResistance MechanismAcetatesResistanceHormone TherapyTissuesAndrogen ReceptorPatient CareCastration Resistant Prostate CancerFutureDisease ResistanceDetectionDiagnosticEnrollmentInhibitorAr Gene
Grant awards (20)
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$647,291
R01 · FY2025 · CA
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$328,747
UH3 · FY2025 · CA
Protocol Review & Monitoring Committee$119,502
P30 · FY2025 · CA · contact PI
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$612,180
R01 · FY2024 · CA
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$318,930
UH3 · FY2024 · CA
Protocol Review and Monitoring System$136,318
P30 · FY2024 · CA · contact PI
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$636,857
R01 · FY2023 · CA
Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer$442,930
R01 · FY2023 · CA · contact PI
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$363,463
UH3 · FY2023 · CA
Protocol Review and Monitoring System$140,883
P30 · FY2023 · CA · contact PI
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$632,590
R01 · FY2022 · CA
Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer$454,144
R01 · FY2022 · CA · contact PI
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$160,240
UH2 · FY2022 · CA
Protocol Review and Monitoring System$140,976
P30 · FY2022 · CA · contact PI
Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer$290,930
R01 · FY2021 · CA · contact PI
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$191,368
UH2 · FY2021 · CA
Protocol Review and Monitoring System$136,057
P30 · FY2021 · CA · contact PI
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$653,173
R01 · FY2020 · CA
Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer$541,779
R01 · FY2020 · CA · contact PI
Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer$427,516
R01 · FY2019 · CA · contact PI